Literature DB >> 3327653

Issues in designing sequential stopping rules for monitoring side effects in clinical trials.

A I Goldman1.   

Abstract

In a clinical trial of a new treatment, severe side effects may be a problem, and the trial may have to be stopped if the incidence is too high. We need to anticipate the need for such a decision to halt the trial early, and possibly design formal stopping rules for an excess of untoward events. The work presented here discusses the issues involved in such monitoring in comparison with more conventional analysis of the outcome variable. Stopping rules are derived by application of the sequential probability ratio test (SPRT), followed by computation of the exact size and power and adjustments of the consequent rules to achieve chosen operating characteristics appropriate to a monitoring situation. Rules are also derived from a Bayesian approach. These rules are applied to an illustrative trial and compared to the actual conditions that lead to the closing the trial.

Mesh:

Substances:

Year:  1987        PMID: 3327653     DOI: 10.1016/0197-2456(87)90153-x

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  4 in total

1.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Authors:  Hedy L Kindler; Theodore G Karrison; David R Gandara; Charles Lu; Lee M Krug; James P Stevenson; Pasi A Jänne; David I Quinn; Marianna N Koczywas; Julie R Brahmer; Kathy S Albain; David A Taber; Samuel G Armato; Nicholas J Vogelzang; Helen X Chen; Walter M Stadler; Everett E Vokes
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Authors:  Smita S Joshi; Daniel V T Catenacci; Theodore G Karrison; Jaclyn D Peterson; Mark M Zalupski; Amikar Sehdev; James Wade; Ahad Sadiq; Vincent J Picozzi; Andrea Amico; Robert Marsh; Mark F Kozloff; Blase N Polite; Hedy L Kindler; Manish R Sharma
Journal:  Clin Cancer Res       Date:  2019-09-26       Impact factor: 12.531

3.  Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.

Authors:  Robert de W Marsh; Mark S Talamonti; Marshall S Baker; Mitchell Posner; Kevin Roggin; Jeffrey Matthews; Daniel Catenacci; Mark Kozloff; Blase Polite; Michele Britto; Chi Wang; Hedy Kindler
Journal:  J Surg Oncol       Date:  2017-10-16       Impact factor: 3.454

4.  ADAPT: the wrong way to stop a clinical trial.

Authors:  Steven E Nissen
Journal:  PLoS Clin Trials       Date:  2006-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.